Bosutinib (SKI-606)

Catalog No. A10161

Bosutinib (SKI-606) is a tyrosine kinase inhibitor undergoing research for use in the treatment of cancer.
  • Li Li, .et al. Evidence for activated Lck protein tyrosine kinase as the driver of proliferation in acute myeloid leukemia cell, CTV-1, Leukemia Res, 2019, 78:12-20 PMID: 30660961
Catalog Num A10161
M. Wt 530.4
Formula C26H29Cl2N5O3
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 380843-75-4
Synonyms SKI-606, SKI606
SMILES CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
Bosutinib (SKI-606) is a tyrosine kinase inhibitor undergoing research for use in the treatment of cancer.
Targets
Abl (Cell-free assay) Src (Cell-free assay)
1 nM1.2 nM
In vitro DMSO 100 mg/mL (188.51 mM)
Water <1 mg/mL (<1 mM)
Ethanol 2 mg/mL (3.77 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 18.85 mL 94.27 mL 188.54 mL
0.5 mM 3.77 mL 18.85 mL 37.71 mL
1 mM 1.89 mL 9.43 mL 18.85 mL
5 mM 0.38 mL 1.89 mL 3.77 mL

*The above data is based on the productmolecular weight 530.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.